IBRX vs. ROIV, ASND, BPMC, RVMD, BBIO, LNTH, LEGN, ELAN, CYTK, and NUVL
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Lantheus (LNTH), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.
ImmunityBio vs.
ImmunityBio (NASDAQ:IBRX) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
ImmunityBio currently has a consensus target price of $13.58, indicating a potential upside of 335.36%. Roivant Sciences has a consensus target price of $17.93, indicating a potential upside of 59.93%. Given ImmunityBio's stronger consensus rating and higher possible upside, equities research analysts clearly believe ImmunityBio is more favorable than Roivant Sciences.
ImmunityBio has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
Roivant Sciences has a net margin of 3,827.42% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Roivant Sciences' return on equity.
Roivant Sciences has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 83.4% of ImmunityBio shares are owned by company insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Roivant Sciences received 42 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 77.27% of users gave Roivant Sciences an outperform vote while only 30.00% of users gave ImmunityBio an outperform vote.
In the previous week, ImmunityBio had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.58 beat ImmunityBio's score of 0.48 indicating that Roivant Sciences is being referred to more favorably in the news media.
Summary
Roivant Sciences beats ImmunityBio on 11 of the 18 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunityBio Competitors List
Related Companies and Tools
This page (NASDAQ:IBRX) was last updated on 1/24/2025 by MarketBeat.com Staff
Free IBRX Stock Alerts